Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression

Oncogene

Volumn 34, Issue 42, 2015, Pages 5395-5405

  Goka, E T ^a   Lippman, M E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HACE1 PROTEIN; MATRIGEL; NEU DIFFERENTIATION FACTOR; PROTEIN; RAC1 PROTEIN; SHORT HAIRPIN RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HACE1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UBIQUITINATION; WILD TYPE; ANIMAL; BREAST NEOPLASMS; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; MICE; MICE, SCID; MUTAGENESIS, INSERTIONAL; RAC1 GTP-BINDING PROTEIN; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84945465998     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.468     Document Type: Article

References (44)

1. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
3. Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 1386-1389.
4. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002; 15: 1318-1325.
5. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992; 89: 10578-10582.
6. Marcotte R, Muller WJ. Signal transduction in transgenic mouse models of human breast cancer-implications for human breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13: 323-335.
7. Lu T, Jackson MW, Singhi AD, Kandel ES, Yang M, Zhang Y et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci USA 2009; 106: 16339-16344.
8. Tina E, Lindqvist BM, Gabrielson M, Lubovac Z, Wegman P, Wingren S. The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors. BMC Cancer 2012; 12: 350.
9. Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV, Grundy PE et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet. 2004; 13: 2061-2074.
10. Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H et al. Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer. Anticancer Res 2008; 28: 1581-1584.
11. Hyytinen ER, Saadut R, Chen C, Paull L, Koivisto PA, Vessella RL et al. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 2002; 34: 306-312.
12. Sakata M, Kitamura YH, Sakuraba K, Goto T, Mizukami H, Saito M et al. Methylation of HACE1 in gastric carcinoma. Anticancer Res 2009; 29: 2231-2233.
13. Zhang L, Anglesio MS, O'Sullivan M, Zhang F, Yang G, Sarao R et al. The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat Med 2007; 13: 1060-1069.
14. Nethe M, Hordijk PL. The role of ubiquitylation and degradation in RhoGTPase signalling. J Cell Sci 2010; 123: 4011-4018.
15. Visvikis O, Maddugoda MP, Lemichez E. Direct modifications of Rho proteins: deconstructing GTPase regulation. Biol Cell 2010; 102: 377-389.
16. Torrino S, Visvikis O, Doye A, Boyer L, Stefani C, Munro P et al. The E3 ubiquitinligase HACE1 catalyzes the ubiquitylation of active Rac1. Dev Cell 2011; 21: 959-965.
17. Castillo-Lluva S, Tan CT, Daugaard M, Sorensen PH, Malliri A.. The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation. Oncogene 2012.
18. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000; 19: 3013-3020.
19. Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-Haber C, Sosa MS, Kazanietz MG. Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal 2012; 24: 353-362.
20. Yang C, Liu Y, Lemmon MA, Kazanietz MG.. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol Cell Biol 2006; 26: 831-842.
21. Hernandez E, De La Mota-Peynado A, Dharmawardhane S, Vlaar CP. Novel inhibitors of Rac1 in metastatic breast cancer. P R Health Sci J 2010; 29: 348-356.
22. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992; 70: 401-410.
23. Melino G, Gallagher E, Aqeilan RI, Knight R, Peschiaroli A, Rossi M et al. Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ 2008; 15: 1103-1112.
24. Lachance V, Degrandmaison J, Marois S, Robitaille M, Genier S, Nadeau S et al. Ubiquitylation and activation of a Rab GTPase is promoted by a beta2AR-HACE1 complex. J Cell Sci 2014; 127(Pt 1): 111-123.
25. Tang D, Xiang Y, De Renzis S, Rink J, Zheng G, Zerial M et al. The ubiquitin ligase HACE1 regulates Golgi membrane dynamics during the cell cycle. Nat Commun 2011; 2: 501.
26. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, Der CJ. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem 2007; 282: 35666-35678.
27. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor betainduced cell motility. J Biol Chem 2004; 279: 24505-24513.
28. Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM et al. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 2010; 40: 877-892.
29. Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res 2006; 66: 9591-9600.
30. Laurin M, Huber J, Pelletier A, Houalla T, Park M, Fukui Y et al. Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis. Proc Natl Acad Sci USA 2013; 110: 7434-7439.
31. Kim IY, Yong HY, Kang KW, Moon A. Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett 2009; 275: 227-233.
32. Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG et al. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Res Treat 2014; 144: 503-517.
33. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 1997; 151-156.
34. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96: 443-448.
35. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003; 1: 362-375.
36. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003; 100: 5974-5979.
37. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992; 28: 644-648.
38. Sakata M, Kitamura YH, Sakuraba K, Goto T, Mizukami H, Saito M et al. Methylation of HACE1 in gastric carcinoma. Anticancer Res 2009; 29: 2231-2233.
39. Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H et al. Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer. Anticancer Res 2008; 28: 1581-1584.
40. Sakata M, Yokomizo K, Kitamura Y, Sakuraba K, Shirahata A, Goto T et al. Methylation of the HACE1 gene is frequently detected in hepatocellular carcinoma. Hepatogastroenterology 2013; 60: 781-783.
41. Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 2004; 23: 9369-9380.
42. Kawazu M, Ueno T, Kontani K, Ogita Y, Ando M, Fukumura K et al. Transforming mutations of RAC guanosine triphosphatases in human cancers. Proc Natl Acad Sci USA 2013; 110: 3029-3034.
43. Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol 2008; 439: 111-129.
44. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690-701.